Tau Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 working days
DelveInsight’s, “Tau Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Tau Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Tau Inhibitors: Overview
Microtubule-associated protein tau is characterized by the fact that it is an intrinsically disordered protein due to its lack of a stable conformation and high flexibility. Intracellular inclusions of fibrillar forms of tau with a ?-sheet structure accumulate in the brain of patients with Alzheimer's disease and other tauopathies. Accordingly, detachment of tau from microtubules and transition of tau from a disordered state to an abnormally aggregated state are essential events preceding the onset of tau-related diseases. Early anti-tau therapies were based mainly on inhibition of kinases or tau aggregation, or on stabilization of microtubules, but most of these approaches have been discontinued because of toxicity and/or lack of efficacy. Most of the tau-targeting approaches that are currently in clinical trials are immunotherapies. Tau is likely to be a better target than A? once cognitive deficits manifest, because the tau burden correlates better with clinical impairments than does the A? burden.
'Tau Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tau Inhibitors pipeline landscape is provided which includes the disease overview and Tau Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Tau Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tau Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Tau Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tau Inhibitors Emerging Drugs
Further product details are provided in the report……..
Tau Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Tau Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Tau Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau Inhibitors drugs.
Tau Inhibitors Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Tau Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Tau Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Tau Inhibitors: Overview
Microtubule-associated protein tau is characterized by the fact that it is an intrinsically disordered protein due to its lack of a stable conformation and high flexibility. Intracellular inclusions of fibrillar forms of tau with a ?-sheet structure accumulate in the brain of patients with Alzheimer's disease and other tauopathies. Accordingly, detachment of tau from microtubules and transition of tau from a disordered state to an abnormally aggregated state are essential events preceding the onset of tau-related diseases. Early anti-tau therapies were based mainly on inhibition of kinases or tau aggregation, or on stabilization of microtubules, but most of these approaches have been discontinued because of toxicity and/or lack of efficacy. Most of the tau-targeting approaches that are currently in clinical trials are immunotherapies. Tau is likely to be a better target than A? once cognitive deficits manifest, because the tau burden correlates better with clinical impairments than does the A? burden.
'Tau Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tau Inhibitors pipeline landscape is provided which includes the disease overview and Tau Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Tau Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tau Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Tau Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Tau Inhibitors.
This segment of the Tau Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tau Inhibitors Emerging Drugs
- TRx0237: TauRx Therapeutics
- IONIS-MAPTRx: Ionis Pharmaceuticals
Further product details are provided in the report……..
Tau Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Tau Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Tau Inhibitors
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Tau Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau Inhibitors drugs.
Tau Inhibitors Report Insights
- Tau Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Tau Inhibitors drugs?
- How many Tau Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tau Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tau Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tau Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- TauRx Therapeutics
- Ionis Pharmaceuticals
- UCB Biopharma
- Alterity Therapeutics
- Pinteon Therapeutics
- Voyager Therapeutics
- Oligomerix
- TRx0237
- IONIS-MAPTRx
- Bepranemab
- ATH 434
- PNT-001
- Research programme: gene therapies
- OLX-07010
Introduction
Executive Summary
Tau Inhibitors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
TRx0237: TauRx Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IONIS-MAPTRx: Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
ATH 434: Alterity Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Tau Inhibitors Key Companies
Tau Inhibitors Key Products
Tau Inhibitors- Unmet Needs
Tau Inhibitors- Market Drivers and Barriers
Appendix
Executive Summary
Tau Inhibitors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
TRx0237: TauRx Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IONIS-MAPTRx: Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
ATH 434: Alterity Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Tau Inhibitors Key Companies
Tau Inhibitors Key Products
Tau Inhibitors- Unmet Needs
Tau Inhibitors- Market Drivers and Barriers
Appendix
